1. Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial. (10th April 2018) Authors: Wirsching, H -G; Tabatabai, G; Roelcke, U; Hottinger, A F; Jörger, F; Schmid, A; Plasswilm, L; Schrimpf, D; Mancao, C; Capper, D; Conen, K; Hundsberger, T; Caparrotti, F; von Moos, R; Riklin, C; Felsberg, J; Roth, P; Jones, D T W; Pfister, S; Rushing, E J Journal: Annals of oncology Issue: Volume 29:Number 6(2018) Page Start: 1423 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. LBA19Fluoropyrimidine (FP) + bevacizumab (BEV) + atezolizumab vs FP/BEV in BRAFwt metastatic colorectal cancer (mCRC): Findings from Cohort 2 of MODUL – a multicentre, randomized trial of biomarker-driven maintenance treatment following first-line induction therapy. (23rd October 2018) Authors: Grothey, A; Tabernero, J; Arnold, D; De Gramont, A; Ducreux, M P; O'Dwyer, P J; Van Cutsem, E; Bosanac, I; Srock, S; Mancao, C; Gilberg, F; Winter, J; Schmoll, H-J Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗